Key facts
- Ousia Pharma’s last known valuation is $14.8M (May 2025).
- It has raised $7.2M; the latest was Seed Round ($5.2M) in May 2025.
- Notable investors include InnoFounder, BioInnovation Institute, Omega Funds.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Ousia Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Ousia Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ousia Pharma
Developer of pharmacotherapies designed to improve the health and lives of people living with obesity. The company uses a proprietary targeting approach in which peptides deliver modulators of synaptic plasticity to drive potent and sustained weight loss without compromising safety, enabling patients to treat obesity and metabolic diseases.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2022
- Employees
- 8
- Website
- ousiapharma.com/
- Ownership
- Privately Held (backing)
Ousia Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ousia Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ousia Pharma in its N-PORT filings yet. We sweep new filings monthly.